Apeptico: At the Long Night of Research

Vienna, Austria, 20th April, 2012: APEPTICO Forschung und Entwicklung GmbH has been nominated to present its innovative life-science projects at the “long night of research” ("Lange Nacht der Forschung") in Vienna, during the evening of April 27th, 2012. The "Lange Nacht der Forschung" aims to introduce state-of-the-art research results, innovations and inventions to the Austrian public. APEPTICO will present its peptide technology in the exhibition "The World of Innovation" at the Patent Office of Austria.

Most recently, APEPTICO’s patent “Prevention and Treatment of Hyperpermeability” was awarded the INVENTUM nomination based on a decision of a jury composed of experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology. APEPTICO’s invention ranks among the 10 most innovative inventions of the year 2011 in Austria.

About Apeptico GmbH

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO’s development platform PEPBASETM combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.